Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market

VEENENDAAL, The Netherlands - Nucletron BV, the innovative cancer radiation solutions company, today announced the creation of an exclusive partnership and plan to merge with sector peer Isodose Control BV for an undisclosed sum. The two companies, headquartered in Veenendaal and Ede, the Netherlands, are complementary and the combination will strengthen Nucletron’s position as global leader in the market for high-precision radiation therapy equipment and software, or brachytherapy.

The merger plans were announced by the two companies CEOs on Monday June 1 in Toronto, Canada, at the American Brachytherapy Society’s annual conference.

“By combining strengths we will become the undisputed global market leader in brachytherapy, which offers quality, safe and effective treatment options for the most frequently occurring kinds of cancer,” said Jos Lamers, CEO of Nucletron.

Nucletron is the world’s number one medical equipment provider in the brachytherapy market, with a strong focus on customer support; Isodose Control has grown in six years to become number three and has an impressive product innovation track record.

“Isodose Control has developed a range of innovative brachytherapy products and has a promising range in development. Together with Nucletron, we look forward to speeding up the market introductions of these innovations to healthcare institutions and their patients worldwide,” said Eric van’t Hooft, CEO of Isodose Control BV.

Van ‘t Hooft in fact founded Nucletron in 1975 and built it into a successful technology company, before merging it to Dutch stock exchange-listed Delft Instruments NV in 1994. Van ‘t Hooft left nine years later to found Isodose Control in 2003. Van’t Hooft, who was awarded a knighthood and the title Commander in the order of the Dutch Lion for his services to science, will become a member of the Executive Management team of Nucletron and will hold the title of Founder.

Nucletron reported a record EBITDA of EUR 17 million on net sales of EUR 112.4 million in 2008.

Growing demand for cancer radiation therapy

According to the World Health Organisation, new cases of cancer will jump from 11.3 million in 2007 to 15.5 million in 2030, influenced in part by an increasing and aging global population. The global market for radiation therapy equipment is projected to reach $3.9 billion by 2015, according to estimates by Global Industry Analysts. Brachytherapy is regarded as one of the best treatment options for a growing range of cancer types, including cancer of the prostate, breast and cervix. The radiation source used for killing the cancer cells and shrinking the tumours is placed in or close to the tumour itself. This precision approach allows doctors to concentrate the dose of radiation in a smaller area, significantly reducing damage to nearby healthy cells and organs. In addition, there are significantly fewer side effects and treatment times are significantly shorter - usually spanning a few days instead of weeks as required in the case of external beam radiotherapy.

About Nucletron

Nucletron, a leader in high-precision radiation therapy, works closely with medical teams to realize innovative oncology solutions that improve patient care. Established in 1975, the company specializes in the development, manufacture, sales, service and ongoing support of some of the world’s most innovative cancer treatment products. Nucletron, based in Veenendaal, the Netherlands, has offices in 15 countries and a strong market presence in over 100 countries world-wide. For more information, visit www.nucletron.com.

About Isodose Control

Isodose Control, headquartered in Ede, the Netherlands, is an innovation-led medical technology company that specializes in developing and distributing next generation brachytherapy solutions. Together with oncologists and scientists world-wide, Isodose Control works continuously to improve brachytherapy techniques, in order to provide cancer treatment centres with the most refined and patient-friendly treatment techniques for their patients.

Source: Nucletron B V

For further information: Media contact Europe, Middle East, Africa and Asia; Media Wise: Emma Robson, +31(0)20-6185518 (office), +31(0)6-55146437 (mobile), emma at mediawise.nl; Jeroen Bruning, +31(0)62-25-25-943, jeroen at mediawise.nl; Media Contact Americas, Rose Communications, Danielle Davis, +1-443-834-6725, ddavis at rosecomm.com